• 1
    Schmoor C, Sauerbrei W, Bastert G, Bojar H, Schumacher M. Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. Eur J Cancer. 2001; 37: 11231131.
  • 2
    Buzdar AU, Kau SW, Hortobagyi GN, et al. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer. 1992; 69: 448452.
  • 3
    Walker MJ, Osborne MD, Young DC, Schneebaum S, La Valle GJ, Farrar WB. The natural history of breast cancer with more than 10 positive nodes. Am J Surg. 1995; 169: 575579.
  • 4
    Peters WP, Shpall EJ, Jones RB, et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988; 6: 13681376.
  • 5
    Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993; 11: 11321143.
  • 6
    Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 1997; 15: 18701879.
  • 7
    Gianni AM, Siena S, Bregni M, et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol. 1997; 15: 23122321.
  • 8
    Canellos GP. Selection bias in trials of transplantation for metastatic breast cancer: have we picked the apple before it was ripe? J Clin Oncol. 1997; 15: 31693170.
  • 9
    Peters WP, Rosner GL, Vredenburgh JJ, et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary beast cancer: a report of CALBG 9082, SWOG 9114, and NCIC MA-13. J Clin. Oncol. 2005; 23: 21912200.
  • 10
    Kornblith AB, Holland JC. Model for quality-of-life research from the Cancer and Leukemia Group B: the telephone interview, conceptual approach to measurement, and theoretical framework. J Natl Cancer Inst Monogr. 1996; 20: 5562.
  • 11
    Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol. 1984; 2: 472483.
  • 12
    Clinch J. The Functional Living Index-Cancer: ten years later. In: SpilkerB, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven, 1996: 215225.
  • 13
    Morrow GR, Lindke J, Black P. Measurement of quality of life in patients: psychometric analyses of the Functional Living Index-Cancer (FLIC). Qual Life Res. 1992; 1: 287296.
  • 14
    Derogatis LR. The Psychosocial Adjustment to Illness Scale (PAIS). J Psychosom Res. 1986; 30: 7791.
  • 15
    McCorkle R. The measurement of symptom distress. Semin Oncol Nurs. 1987; 3: 248256.
  • 16
    Holland JC, Kornblith AB, Cella DF, et al. A sociodemographic data collection model for cooperative clinical trials [abstract]. Proc Am Soc Clin Oncol. 1992; 11: 157.
  • 17
    Winer EP, Lindley C, Hardee M, et al. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support. Psychooncology. 1999; 8: 167176.
  • 18
    Del Mastro L, Costantini M, Morasso G, et al. Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients. Eur J Cancer. 2002; 38: 359366.
  • 19
    Bottomley A, Therasse P. Quality of life in patients undergoing systemic therapy for advanced breast cancer. Lancet Oncol. 2002; 3: 620628.
  • 20
    Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet. 2000; 356: 13841391.
  • 21
    Rodenhuis S, Bontenbal M, Beex LV, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med. 2003; 349: 716.
  • 22
    Hortobagyi GN, Buzdar AU, Theriault RL, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000; 92: 225233.
  • 23
    Schrama JG, Faneyte IF, Schornagel JH, et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol. 2002; 13: 689698.
  • 24
    Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med. 2000; 342: 10691076.
  • 25
    Lotz JP, Cure H, Janvier M, et al. [Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: results of the national protocol Pegase 04]. Hematol Cell Ther. 1999; 41: 7174.
  • 26
    Nieto Y. The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer. Haematologica. 2003; 88: 201211.
  • 27
    Elfenbein GJ. Stem-cell transplantation for high-risk breast cancer. N Engl J Med. 2003; 349: 8082.
  • 28
    Brandberg Y, Michelson H, Nilsson B, et al. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401. J Clin Oncol. 2003; 21: 36593664.
  • 29
    Hann DM, Garovoy N, Finkelstein B, Jacobsen PB, Azzarello LM, Fields KK. Fatigue and quality of life in breast cancer patients undergoing autologous stem cell transplantation: a longitudinal comparative study. J Pain Symptom Manage. 1999; 17: 311319.
  • 30
    Hensel M, Egerer G, Schneeweiss A, Goldschmidt H, Ho AD. Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation. Ann Oncol. 2002; 13: 209217.
  • 31
    Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized Phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol. 2003; 21: 843850.
  • 32
    Morasso G, Costantini M, Baracco G, Borreani C, Capelli M. Assessing psychological distress in cancer patients: validation of a self-administered questionnaire. Oncology. 1996; 53: 295302.